Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN 201904 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AGN 201904 | DRUG | - |
| esomeprazole | DRUG | - |
Inclusion Criteria: * Healthy Adult Volunteers who have provided written informed consent Exclusion Criteria: * Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease. * Female volunteers who pregnant, nursing, or planning a p...
AGN 201904 is an investigational small molecule being developed for the prevention of peptic ulcer, specifically for preventing aspirin-induced stomach or upper intestinal damage. It is in Phase 1 clinical development and is not yet approved by the FDA.
AGN 201904 is being developed by AbbVie Inc. (NYSE: ABBV). The company is conducting clinical trials to evaluate the drug's safety and efficacy in preventing aspirin-induced gastrointestinal damage.
AGN 201904 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 150 participants.
AGN 201904 was studied in a completed Phase 1 trial (NCT00325715) comparing it to esomeprazole for preventing aspirin-induced stomach or upper intestinal damage in healthy volunteers. The trial enrolled 150 participants in the United States.
No, AGN 201904 is not the same as esomeprazole. In clinical trial NCT00325715, AGN 201904 was compared against esomeprazole as an active control. The two drugs are distinct investigational and approved products, respectively.